Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Abagail M. Delahoussaye"'
Autor:
Abagail M. Delahoussaye, Joseph Abi Jaoude, Morgan Green, Tara N. Fujimoto, Jessica Molkentine, Carolina J. Garcia Garcia, Jason P. Gay, Ningping Feng, Joseph Marszalek, Natalie Fowlkes, Cullen M. Taniguchi
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Both modified FOLFIRINOX (mFFX) and gemcitabine/nab-paclitaxel chemotherapy regimens have been shown to improve clinical outcomes in patients with pancreatic cancer, and are often used interchangeably as the standard of care. Prec
Externí odkaz:
https://doaj.org/article/4b0ba4c0b00742c68c72befa16835872
Autor:
Carolina J. Garcia Garcia, Yanqing Huang, Natividad R. Fuentes, Madeleine C. Turner, Maria E. Monberg, Daniel Lin, Nicholas D. Nguyen, Tara N. Fujimoto, Jun Zhao, Jaewon J. Lee, Vincent Bernard, Meifang Yu, Abagail M. Delahoussaye, Iancarlos Jimenez Sacarello, Emily G. Caggiano, Jae L. Phan, Amit Deorukhkar, Jessica M. Molkentine, Dieter Saur, Anirban Maitra, Cullen M. Taniguchi
Publikováno v:
Gastroenterology. 162:2018-2031
Pancreatic ductal adenocarcinoma (PDAC) has a hypoxic, immunosuppressive stroma that contributes to its resistance to immune checkpoint blockade therapies. The hypoxia-inducible factors (HIFs) mediate the cellular response to hypoxia, but their role
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c1390b3b2b9ef5c73b51f451e38f969
https://doi.org/10.1053/j.gastro.2022.02.024
https://doi.org/10.1053/j.gastro.2022.02.024
Autor:
Sahar B. Fattani, Matthew T. Cribb, Abagail M. Delahoussaye, Nefetiti P. Mims, Natividad R. Fuentes, Cullen M. Taniguchi
Publikováno v:
Cancer Research. 83:2347-2347
Introduction (or Objective): Pancreatic ductal adenocarcinoma (PDAC) is characterized by having an extensive desmoplastic stroma that contributes to its resistance to therapeutic treatments resulting in a poor prognosis. Cancer associated fibroblasts
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b5ab2884d7397fa3931dd301abcb1aca
https://doi.org/10.1158/1538-7445.am2023-2347
https://doi.org/10.1158/1538-7445.am2023-2347
Autor:
Abagail M. Delahoussaye, Joseph Abi Jaoude, Tara N. Fujimoto, Jessica Molkentine, Carolina J. Garcia Garcia, Jason P. Gay, Ningping Feng, Joe Marszalek, Cullen M. Taniguchi
BackgroundBoth modified FOLFIRINOX (mFFX) and gemcitabine/nab-paclitaxel chemotherapy regimens have been shown to improve clinical outcomes in patients with pancreatic cancer, and are often used interchangeably as the standard of care. Preclinical st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ebe1cb45936fc29060dc8d9639f4dc3
https://doi.org/10.1101/2021.09.08.459476
https://doi.org/10.1101/2021.09.08.459476
Autor:
Abagail M, Delahoussaye, Joseph, Abi Jaoude, Morgan, Green, Tara N, Fujimoto, Jessica, Molkentine, Carolina J, Garcia Garcia, Jason P, Gay, Ningping, Feng, Joseph, Marszalek, Natalie, Fowlkes, Cullen M, Taniguchi
Publikováno v:
BMC cancer. 22(1)
Both modified FOLFIRINOX (mFFX) and gemcitabine/nab-paclitaxel chemotherapy regimens have been shown to improve clinical outcomes in patients with pancreatic cancer, and are often used interchangeably as the standard of care. Preclinical studies ofte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::20d62bcfc5025b0abbcc692ca5bd8c05
https://pubmed.ncbi.nlm.nih.gov/35172762
https://pubmed.ncbi.nlm.nih.gov/35172762
Autor:
Anirban Maitra, Carolina J. Garcia Garcia, Jaewon J. Lee, Dieter Saur, Cullen M. Taniguchi, Abagail M. Delahoussaye, Nicholas D. Nguyen, Madeleine C. Turner, Amit Deorukhkar, Yanqing Huang, Tara N. Fujimoto, Vincent Bernard, Natividad R. Fuentes, Daniel Lin, Jun Zhao, Jessica M. Molkentine, Jae L. Phan, Meifang Yu
Background & AimsPancreatic ductal adenocarcinoma (PDAC) has a hypoxic, immunosuppressive stroma, which contributes to its resistance to immune checkpoint blockade therapies. The hypoxia-inducible factors (HIFs) mediate the cellular response to hypox
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ce49a747a0707df05134c5bd5be2e3b
https://doi.org/10.1101/2021.05.21.445190
https://doi.org/10.1101/2021.05.21.445190
Autor:
Tara N. Fujimoto, Meifang Yu, Yanqing Huang, Nicholas D. Nguyen, Cullen M. Taniguchi, Abagail M. Delahoussaye, Manuel A. Estrada
Publikováno v:
Cancer Research. 80:555-555
Background: Pancreatic ductal adenocarcinoma (PDAC) is driven by activating Kras mutations which cause a fragmented mitochondrial phenotype. We recently demonstrated that leflunomide, an FDA-approved drug for rheumatoid arthritis, could be repurposed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ca31d97c997bc270d146edf8d8891da
https://doi.org/10.1158/1538-7445.am2020-555
https://doi.org/10.1158/1538-7445.am2020-555